首页> 外文期刊>Radiation oncology >Target splitting non-coplanar RapidArc radiation therapy for a diffuse sebaceous carcinoma of the scalp: a novel delivery technique
【24h】

Target splitting non-coplanar RapidArc radiation therapy for a diffuse sebaceous carcinoma of the scalp: a novel delivery technique

机译:针对头皮弥漫性皮脂腺癌的靶向分裂非共面RapidArc放射疗法:一种新型的递送技术

获取原文
           

摘要

Background and purpose To compare conventional lateral photon-electron, fixed-beam intensity modulated radiation therapy (IMRT), coplanar and non-coplanar RapidArc for the treatment of a diffuse sebaceous gland carcinoma of the scalp. Methods Comprehensive dosimetry comparisons were performed among 3D-CRT, IMRT and various RapidArc plans. Target coverage, conformity index (CI), homogeneity index (HI) and doses to organs at risk (OAR) were calculated. Monitor unites (MUs) and delivery time of each treatment were also recorded to evaluate the execution efficiency. The influence of target splitting technique and non-coplanar planning on plan quality was discussed. Results IMRT was superior to 3D-CRT concerning targets’ coverage at the sacrifice of larger irradiated brain volumes to low doses. CIs and HIs were better in coplanar RapidArc and non-coplanar RapidArc plans than 3D-CRT and IMRT. Best dose coverage and sparing of OARs were achieved in non-coplanar plans using target splitting technique. Treatment delivery time was longest in the IMRT plan and shortest in the coplanar RapidArc plan without target splitting. The 3%/3 mm gamma test pass rates were above 95% for all the plans. Conclusions Target splitting technique and non-coplanar arcs are recommended for total scalp irradiation.
机译:背景与目的比较传统的侧向光子电子,固定束强度调制放射疗法(IMRT),共面和非共面RapidArc治疗头皮弥漫性皮脂腺癌的方法。方法在3D-CRT,IMRT和各种RapidArc计划之间进行了全面的剂量学比较。计算靶标覆盖率,合格指数(CI),均匀性指数(HI)和高危器官剂量(OAR)。还记录了每个治疗的监测单位(MU)和交付时间,以评估执行效率。讨论了目标分割技术和非共面计划对计划质量的影响。结果IMRT在牺牲较大的照射脑体积而降低剂量的情况下,靶标的覆盖范围优于3D-CRT。与3D-CRT和IMRT相比,共面RapidArc和非共面RapidArc计划中的CI和HI更好。使用目标分割技术,可以在非共面计划中实现OAR的最佳剂量覆盖和节省。 IMRT计划中的治疗交付时间最长,而共面RapidArc计划中的治疗交付时间最短,且没有目标分裂。所有计划的3%/ 3 mm伽玛射线测试合格率均高于95%。结论建议采用靶标分裂技术和非共面弧光进行头皮照射。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号